Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1074506 10.3389/fphar.2023.1074506 Pharmacology Systematic Review Anticancer effects of licochalcones: A review of the mechanisms Deng et al. 10.3389/fphar.2023.1074506 Deng Nan 1 † Qiao Mingming 2 † Li Ying 1 Liang Fengyan 1 Li Jingjing 1 Liu Yanfeng 1 * 1 Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China 2 Chongqing Institute for Food and Drug Control, Chongqing, China

Edited by: Mitesh Patel, Parul University, India

Reviewed by: Jun Wang, Hefei University, China

Mandava Venkata Basaveswara Rao, Krishna University, India

 *Correspondence: Yanfeng Liu, liuyaf8888@sina.com

These authors contributed equally to this work and share first authorship

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

 23 01 2023 2023 14 1074506 19 10 2022 09 01 2023 Copyright © 2023 Deng, Qiao, Li, Liang, Li and Liu. 2023 Deng, Qiao, Li, Liang, Li and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Cancer is a disease with a high fatality rate representing a serious threat to human health. Researchers have tried to identify effective anticancer drugs. Licorice is a widely used traditional Chinese medicine with various pharmacological properties, and licorice-derived flavonoids include licochalcones like licochalcone A, licochalcone B, licochalcone C, licochalcone D, licochalcone E, and licochalcone H. By regulating the expression in multiple signaling pathways such as the EGFR/ERK, PI3K/Akt/mTOR, p38/JNK, JAK2/STAT3, MEK/ERK, Wnt/β-catenin, and MKK4/JNK pathways, and their downstream proteins, licochalcones can activate the mitochondrial apoptosis pathway and death receptor pathway, promote autophagy-related protein expression, inhibit the expression of cell cycle proteins and angiogenesis factors, regulate autophagy and apoptosis, and inhibit the proliferation, migration, and invasion of cancer cells. Among the licochalcones, the largest number of studies examined licochalcone A, far more than other licochalcones. Licochalcone A not only has prominent anticancer effects but also can be used to inhibit the efflux of antineoplastic drugs from cancer cells. Moreover, derivatives of licochalcone A exhibit strong antitumor effects. Currently, most results of the anticancer effects of licochalcones are derived from cell experiments. Thus, more clinical studies are needed to confirm the antineoplastic effects of licochalcones.

 anti-cancer mechanism licochalcone licochalcone A autophagy apoptosis cell cycle 1 Introduction

Cancer seriously affects human health, and in the 21st century, it is expected to become the main cause of death in every country/region (Bray et al., 2018; Keshavarz-Fathi and Rezaei, 2021). Licorice is a widely used traditional Chinese medicine with a variety of pharmacological properties including anti-inflammatory, antioxidant, antidiabetic, anti-asthmatic, and anticancer activities. The pharmacological effects are related to the flavonoids it contains, among which licochalcones have considerable antitumor activity (Hosseinzadeh and Nassiri-Asl, 2015; Pia et al., 2019).

This review systematically reviewed the evidence on the anticancer effects of licochalcones. Licochalcones in licorice comprise licochalcone A (LA), licochalcone B (LB), licochalcone C (LC), licochalcone D (LD), licochalcone E (LE), and licochalcone H (LH) (Figure 1). These licochalcones can activate the mitochondrial apoptosis pathway and the death receptor pathway, promote autophagy-related protein expression, inhibit cell cycle protein expression, and regulate cancer migration-related protein expression via multiple signaling pathways, including EGFR/ERK, PI3K/Akt/mTOR, p38/JNK, JAK2/STAT3, MEK/ERK, Wnt/β-catenin, and MKK4/JNK signaling pathways. Via these mechanisms, licochalcones can induce autophagy and apoptosis in cancer cells, as well as inhibit cancer cell proliferation, migration, and invasion. In tumor tissues, LA can also inhibit angiogenesis and the cellular efflux of anticancer drugs. At present, the antineoplastic effects of LA are most prominent. Various LA derivatives exhibit stronger antitumor effects than LA, and exploring the anticancer mechanisms of these licochalcone derivatives may be a focus of future studies. As most of the licochalcone-induced effects have been examined in cell experiments, more clinical studies are needed to confirm the antitumor effects of licochalcones in the future. Thus, this paper systematically reviewed the literature regarding licochalcone-induced anticancer effects with a focus on LA to provide an overview of the current knowledge and guide further basic and clinical research.

Chemical structure of licochalcones.

 2 Anticancer effects of licochalcones on tumor cells 2.1 Lung cancer

Epidemiological studies have shown that approximately 18 million people are diagnosed with lung cancer each year, and 16 million of them die from this disease (Chen et al., 2014; Hirsch et al., 2017). Licochalcones can induce apoptosis and autophagy, and they inhibit the proliferation, migration, and invasion of lung cancer cells (Keshavarz-Fathi and Rezaei, 2021).

2.1.1 Induction of autophagy

LC3-II is considered to be a characteristic protein of the autophagy process. LA (10–15 μM) can induce autophagy in A549 and H1299 lung cancer cells by increasing the LC3-II/LC3-I ratio, as well as the levels of the autophagy-related proteins ATG5, ATG7, and P62. LA-induced increases in CHOP expression also promote autophagy (Tang et al., 2016; Lin et al., 2019a). Furthermore, LA-induced autophagy in lung cancer cells is associated with the induction of endoplasmic reticulum stress. LA (10 μM) enhances the expression of miR-144-3p, causes unfolded protein response, and triggers autophagy by promoting the accumulation and expression of ATG1, ATG3, ATG6, and ATG16 via activation of the PERK/ATF4/CHOP signaling pathway (Chen et al., 2018).

 2.1.2 Induction of apoptosis

Activation of the mitochondrial apoptosis pathway is closely related to mitochondrial dysfunction. LA (2.5–25 μM) inhibited ATP production and caused mitochondrial dysfunction in H1299 and H322 lung cancer cells by inhibiting hypoxia-induced HIF-1α accumulation and the expression of target genes GLUT1 and PDK1, which induced activation of the mitochondrial apoptosis pathway and apoptosis of cancer cells (Park et al., 2021). LA (10–15 μM) can activate the mitochondrial apoptosis pathway and induce apoptosis in H460 and A549 lung cancer cells by decreasing the levels of Bcl-xL and Bcl-2 while increasing the levels of Bad, Bax, cleaved PARP, and caspase-3 (Tang et al., 2016; Qiu et al., 2017; Lin et al., 2019a). In addition, the survivin protein inhibits caspase-3 activity and prevents cancer cell apoptosis. LA (5–50 μM) downregulated the expression of survivin by inhibiting the EGFR signaling pathway and its downstream kinases ERK1/2 and AKT in H3255, HCC827, H1975, and A549 lung cancer cells (Gao et al., 2021). LB (5–15 μM) inhibited the EGFR and MET signaling pathways and induced mitochondrial dysfunction and endoplasmic reticulum stress in HCC827 lung cancer cells, which induced the loss of MMP, release of cytochrome c, and increased expression of caspases (Oh et al., 2019a).

 2.1.3 Cell cycle block

By inhibiting the expression of MDM2, cyclin B1, CDC2, and CDC25C, LA (10–15 μM) led to cell cycle arrest of H460 and A549 lung cancer cells at the G2/M phase (Qiu et al., 2017; Lin et al., 2019a). Heng et al. found that decreases in the proliferation of lung cancer cells by LA were related to the inhibition of the Wnt/β-catenin signaling pathway (Heng and Cheah, 2021). LB (5–15 μM) caused cell cycle arrest of HCC827 lung cancer cells at the G2/M phase by decreasing the expression of cyclinB1 and CDC2 proteins while increasing p27 expression (Oh et al., 2019a).

 2.1.4 Inhibition of migration and invasion

LA (2–20 μM) inhibited the AKT signaling pathway and the expression of the downstream transcription factor Sp1, which reduced the levels of MMP-1 and MMP-3 and inhibited the migration and invasion of A549 and H460 lung cancer cells (Huang et al., 2014).

 2.1.5 Activation of the immune system

PD-L1 is a key immune checkpoint, and reducing the production of PD-L1 can play a role in immunotherapy. LA (10–50 μM) inhibited the expression of PD-L1 and thereby induced the production of reactive oxygen species (ROS) in A549 lung cancer cells, which inhibited the phosphorylation of 4EBP1, activated the PERK/eIF2α pathway, and ultimately induced apoptosis in cancer cells (Yuan et al., 2021).

 2.2 Liver cancer

Licochalcones can induce apoptosis and inhibit the proliferation, migration, and invasion of hepatocellular carcinoma cells (Keshavarz-Fathi and Rezaei, 2021).

2.2.1 Induction of apoptosis

By inhibiting the PI3K/Akt/mTOR signaling pathway, LA (5–20 μM) activated the mitochondrial apoptosis pathway and promoted the expression of Bax, Bad, and caspase-3, thereby inducing apoptosis in HepG2 cells (Wu et al., 2019). In addition, LA (1–50 μM) induced endoplasmic reticulum stress in HepG2 cells by inducing phosphorylation of VEGFR2, c-Met receptor, and PLCγ1 and enhancing the cytosolic Ca2+ release from the endoplasmic reticulum, which subsequently induced ROS accumulation, the expression of CHOP, as well as caspase-4, -9, and -3, and ultimately cell apoptosis (Choi et al., 2014). Wang et al. found that the production and accumulation of intracellular ROS also activate the mitochondrial apoptosis pathway and increased the expression of Bad, Bax, Bak, PUMA, and caspase-3. The production of intracellular ROS in HepG2 cells is involved in the LA-induced (5–50 μM) downregulation of PDK1 and rubicon by activating the ULK1/Atg13 signaling pathway and increasing the expression of TSC1/2, PRAS40, CTMP, and PP2A. Moreover, LA activates the death receptor pathway and caspase cascade by increasing the expression of DR3, DR5, and Fas. LA also decreases the expression of the survival factor PKCε, p70S6K, and Akt. Through these effects, LA (30–70 μM) finally induces apoptosis in HepG2 cells (Niu et al., 2018; Wang et al., 2018). LA (70 μM) can induce apoptosis of HepG2 cells by regulating the MAPK and FoxO signaling pathways (Wang et al., 2021). Likewise, LB (10–120 μM) induces apoptosis in HepG2 cells by activating the extrinsic apoptotic pathway (i.e., increasing the expression of TNFR1, Fas, Fas-L, caspase-8, JUN, and Fos) and mitochondrial apoptosis pathway (i.e., increasing the expression of Bak, caspase-9, and caspase-3) (Wang et al., 2019). LB (120 μM) can promote the apoptosis of HepG2 cells by regulating microRNAs (miRNAs) including miR-29b-3p and miR-96-5p (Wang and Wang, 2021). By inhibiting the expression of EGFR and MET, promoting the accumulation of intracellular ROS, activating the mitochondrial apoptosis pathway, increasing the expression of Bid, Bad, and cleaved PARP, and reducing the expression of Bcl-xL and Mcl-1, LD (5–20 μM) induced apoptosis in HCC827 cells (Oh et al., 2020).

 2.2.2 Cell cycle block

LA (30–70 μM) blocked the cell cycle of HepG2 cells at the G2/M transition by increasing the expression of Weel, P21, and JNK1 while decreasing the expression of survivin, cyclin B1, cyclin D1, and CDK1. Further research showed the observed effects were related to the inhibition of the p38/JNK/ERK signaling pathway (Chen et al., 2017; Wang et al., 2018). By decreasing the expression of CDK1, cyclin B1, CHK2, CDC14B, and CDC7 and increasing the expression of p21, LB (10–120 μM) caused the cell cycle arrest of HepG2 cells at the G2/M phase (Wang et al., 2019). LB (10–20 μM) blocked the cell cycle of HepG2 and Huh7 cells at the G2/M phase via increased p27 expression and decreased cyclin B1 and Cdc2 levels (Zhang et al., 2022). By decreasing the expression levels of cyclin B1 and CDC2 and increasing those of p21 and p27, LD (5–20 μM) induced a cell cycle arrest of HCC827 cells at the G2/M phase (Oh et al., 2020).

 2.2.3 Inhibition of migration and invasion

By downregulating the expression of uPA and MMP9 through inhibition of the MKK4/JNK and NF-κB signaling pathways, LA (5–20 μM) inhibited the migration and invasion of HA22T/VGH and SK-Hep-1 cells (Tsai et al., 2014; Wu et al., 2018a).

 2.3 Breast cancer

Research has shown that licochalcones can induce apoptosis and autophagy and inhibit the proliferation, migration, invasion, and angiogenesis of breast cancer cells (Keshavarz-Fathi and Rezaei, 2021).

2.3.1 Induction of autophagy

LA (5–50 μM) can inhibit the PI3K/Akt/mTOR signaling pathway, which increases the expression of LC3-II protein and ultimately induces autophagy in MCF-7 cells (Xue et al., 2018).

 2.3.2 Induction of apoptosis

By inhibiting the PI3K/Akt/mTOR signaling pathway, LA (5–50 μM) activated the mitochondrial apoptosis pathway, reduced the expression of Bcl-2, and promoted the expression of Bax and caspase-3, thereby inducing the apoptosis in MCF-7 cells (Huang et al., 2019). By decreasing the mitochondrial membrane potential and inducing ROS production, LA (5–50 μM) upregulated the expression of Bid, Bad and cleaved PARP, downregulated the expression of Bcl-2 and Bcl-xL, and induced the apoptosis in MCF-7 and MDA-MB-231 cells. The authors suggested that these effects were related to the inhibition of Sp1 (Kang et al., 2017a). Via increases in the level of acylcarnitine and inhibition of prostaglandin reductase 1 expression, LA (1–100 μM) caused respiratory dysfunction in HCC38 TNBC cells and thus induced cancer cells apoptosis (Roberts et al., 2017). LB (10–50 μM) induced apoptosis in MCF-7 cells by increasing the expression of Bid, Bad, cleaved PARP, and caspase-3 while decreasing the expression of Bcl-2 (Yu et al., 2016).

 2.3.3 Cell cycle block

By downregulating the expression of Sp1, LA inhibited the proliferation of MCF-7 and MDA-MB-231 cells via increases in the expression of the proteins p21 and p27 and decreases in the expression of Mcl-1 and survivin (Kang et al., 2017a). LA (5–15 μg/mL) also blocked the cell cycle of MCF-7 cells at the G1 phase via reduced cyclin D1 expression (Bortolotto et al., 2017). By reducing the expression of cyclin D1 and increasing the expression of p21, LA (5–50 μM) led to cell cycle arrest of MCF-7 cells at the G0/G1 phase (Huang et al., 2019). The overexpression of PRMT6 in human breast cancer is related to tumorigenesis (Cheng and Bedford, 2011), and LA (10–100 μM) caused the cell cycle arrest of MCF-7 cells at the G2/M phase by inhibiting PRMT6 expression and subsequently p53 expression (Gong et al., 2020). By downregulating the expression levels of cyclin A, CDK2, and CDC25A and increasing the level of p21, LB (10–50 μM) induced the cell cycle arrest of MCF-7 cells at the S phase (Yu et al., 2016). By decreasing the expression of CDK4, CDK2, cyclin A, and cyclin D1, LE (7–14 mg/kg) inhibited the proliferation of MDA-MB 231 cells in mice (Kwon et al., 2013).

 2.3.4 Inhibition of migration and invasion

LA (5–40 μΜ) inhibited the migration and invasion of MDA-MB-231 cells by suppressing the expression of E-cadherin and vimentin via inhibition of the p38 MAPK and AKT signaling pathways (Huang et al., 2019). By decreasing the expression of uPA and MMP-9, LE (7–14 mg/kg) inhibited the migration and invasion of MDA-MB 231 cells in mice (Kwon et al., 2013).

 2.3.5 Inhibition of angiogenesis

Via downregulation of VEGF-A, LE (7–14 mg/kg) inhibited angiogenesis in cancer tissue in a xenograft mouse model using MDA-MB 231 breast cancer cells (Kwon et al., 2013).

 2.4 Oral carcinoma

Head and neck cancer is the seventh most common cancer in the world, and almost half of the tumors are oral carcinomas. Oral squamous cell carcinoma is the most common form of oral cancer, with a poor prognosis and high mortality (Vitorio et al., 2020). Licochalcones can induce apoptosis and inhibit the proliferation, migration, and invasion of oral carcinoma cells (Keshavarz-Fathi and Rezaei, 2021).

2.4.1 Induction of apoptosis

By activating the mitochondrial apoptosis pathway and increasing the expression of Bax, Bid, cleaved PARP, and caspase-3, LA (10–40 μM) induced apoptosis in HN22 and HSC4 cells (Cho et al., 2014). Similarly, by activating the mitochondrial apoptosis pathway and the caspase cascade, LA (5–100 μg/mL) induced apoptosis in SCC-25 cells (Zeng et al., 2014). In addition to its effects on the mitochondrial apoptosis pathway, LA (IC50 = 50 μM) activated the FasL-mediated death receptor pathway and upregulated the caspase-8 and -3 levels in KB cells (Kim et al., 2014). In pharyngeal squamous carcinoma FaDu cells, LA (10–100 μM) activated the death receptor pathway by increasing the expression of TRAIL via stimulation of the ERK1/2 and p38 MAPK signaling pathways. Moreover, the activation of the ERK1/2 and p38 MAPK signaling pathways upregulated the p53 expression, thereby increasing the levels of Bad, Bax, caspase-3, -8, and -9, as well as the release of cytochrome c (Yang et al., 2014; Park et al., 2015). LB (10–30 μM) can also activate the death receptor pathway (i.e., increased expression of DR 4 and DR5) and induce endoplasmic reticulum stress (i.e., increased CHOP expression) in HN22 and HSC4 cells, which causes mitochondrial membrane depolarization, upregulates the expression of Bax, cleaved PARP, and caspase-3, and downregulates the expression of survivin, Bcl-xL, and Mcl-1 (Oh et al., 2016). By inhibiting the JAK2/STAT3 signaling pathway leading to activation of the death receptor pathway (i.e., increased expression of DR4 and DR5), endoplasmic reticulum stress (i.e., elevated ROS and CHOP levels), and mitochondrial apoptosis pathway (i.e., upregulated expression of p21, Bax, Bid, Apaf-1, and cleaved PARP; downregulated expression of Bcl-2, Mcl-1, and survivin), LC (10–50 μM) and LD (10–30 μM) induced apoptosis in HN22 and HSC4 cells (Oh et al., 2018; Seo et al., 2019). LD (12.5–50 μg/mL) induced apoptosis in pharyngeal squamous carcinoma FaDu cells by increasing Fas-L, p53, Bax, Bid, and caspase-3 expression while decreasing the expression of Bcl-2 by activating the death receptor and mitochondrial apoptosis pathways (Yu et al., 2017). LH (10–30 μM) induced apoptosis in HSC2 and HSC3 cells by downregulating the expression of Bcl-2 and Bcl-xL and upregulating the expression of Bax and Bad via inhibition of Matr3 expression (Nho et al., 2019). LH (5–20 μM) can also induce apoptosis in HN22 and HSC4 cells by activating the death receptor pathway, endoplasmic reticulum stress, and mitochondrial apoptosis pathway via inhibition of the JAK/STAT3 signaling pathway (Oh et al., 2019b).

 2.4.2 Cell cycle block

LA (5–100 μg/mL) led to cell cycle arrest of SCC-25 cells at the S and G2/M phases (Zeng et al., 2014). Further research showed that LA (10–40 μM) inhibited the proliferation of HN22 and HSC4 cells by inhibiting Sp1 expression and regulating its downstream proteins including p27, p21, and cyclin D1 (Cho et al., 2014). Both LB and LD (10–30 μM) can induce G1 phase arrest in HN22 and HSC4 cells by increasing the p21 and p27 levels and decreasing the level of cyclin D1 (Oh et al., 2016; Seo et al., 2019). Likewise, LH (5–20 μM) induced G1 phase arrest in HN22 and HSC4 cells by increasing the p21 and p27 levels and decreasing the level of cyclin D1 via inhibition of the JAK/STAT3 signaling pathway (Oh et al., 2019b).

 2.4.3 Inhibition of migration and invasion

LA (25–100 μM) inhibited the migration and invasion of SCC4 and CAL-27 cells by downregulating the IGF-1, MMP-2, and MMP-9 levels via inhibition of the PI3K/AKT signaling pathway (Hao et al., 2019). LA (25–100 μg/mL) can also inhibit the migration and invasion of SCC-25 cells by decreasing MMP-2 expression while increasing the levels of TIMP and E-cadherin (Shen et al., 2014).

 2.5 Esophageal cancer

Esophageal cancer belongs to the head and neck cancers and is the sixth leading cause of cancer-related death. Its incidence rate increases every year (Zhang et al., 2021). Licochalcones can induce apoptosis and inhibit proliferation in esophageal cancer cells (Keshavarz-Fathi and Rezaei, 2021).

2.5.1 Induction of apoptosis

LB (5–20 μM) induced apoptosis in KYSE-450 and KYSE-510 cells by inhibiting the JAK2/STAT3 signaling pathway and decreasing the expression of Mcl-1 (Song et al., 2020). Via inhibition of the JNK/p38 MAPK signaling pathway, LC (10–50 μM) induced endoplasmic reticulum stress (i.e., increased GRP78 and CHOP expression) and activated the mitochondrial apoptosis pathway in various esophageal squamous carcinoma cells, including KYSE-30, KYSE-70, KYSE-410, KYSE-450, and KYSE-510 cells (Kwak et al., 2020a). LH (5–20 μM) induced the apoptosis in KYSE-30 and KYSE-450 cells by activating the death receptor pathway, mitochondrial apoptosis pathway, and endoplasmic reticulum stress via increased DR4, DR5, CHOP, p21, Bax, Bid, Apaf-1, and cleaved PARP expression, stimulated ROS production, and decreased expression of Bcl-2, Mcl-1, and survivin (Kwak et al., 2020b).

 2.5.2 Cell cycle block

LB (5–20 μM) induced G2/M phase cell cycle arrest in KYSE-450 and KYSE-510 cells (Song et al., 2020). LH (5–20 μM) blocked the cell cycle of KYSE-30 and KYSE-450 cells at the G2/M phase by downregulating CDC2 and cyclin B1 expression and upregulating p21 and p27 (Kwak et al., 2020b).

 2.6 Gastric cancer

Stomach cancer is the fifth most commonly diagnosed cancer and the third leading cause of cancer death (Bray et al., 2018). Research has shown that licochalcones can induce apoptosis and inhibit proliferation in gastric cancer cells (Keshavarz-Fathi and Rezaei, 2021).

2.6.1 Induction of apoptosis

By activating the ERK, JNK, and p38 MAPK signaling pathways and inhibiting the PI3K/AKT signaling pathway, LA (20–100 μM) promoted the intracellular ROS generation and stimulated both the mitochondrial apoptosis pathway and caspase cascade in BGC-823 cells (Hao et al., 2015). Via activation of the mitochondrial apoptosis pathway, induction of Bax, Bad, cleaved PARP, caspase-3, -8, and -9 expression, and decrease in Bcl-2 expression, LA induced the apoptosis in five gastric cell lines including GES-1, MKN-28, SGC7901, AGS, and MKN-45 cells. The respective IC50 values of LA were 92.7, 42.0, 40.8, 41.1, and 40.7 μM (Xiao et al., 2011; Lin et al., 2017). Moreover, the inhibitory effect of LA (10–50 μM) on the AKT signaling pathway can downregulate the expression of hexokinase 2A and inhibit glycolysis, thereby inducing apoptosis of MKN45 and SGC7901 cells (Wu et al., 2018b).

 2.6.2 Cell cycle block

By increasing retinoblastoma expression and decreasing cyclin A, cyclin B, and MDM2 expression, LA (5–50 μM) caused the cell cycle arrest of MKN-28, AGS, and MKN-45 cells at the G2/M transition (Xiao et al., 2011; Lin et al., 2017).

 2.7 Colon cancer

Globally, colon cancer is the second most common cancer in women and the third most common cancer in men with slightly increased case numbers in men (O'Keefe, 2016). Licochalcones can induce apoptosis and inhibit proliferation in colon cancer cells (Keshavarz-Fathi and Rezaei, 2021).

2.7.1 Induction of apoptosis

LA (10–40 μM) can enhance the production of intracellular ROS by inhibiting the expression of thioredoxin reductase-1, which activates the mitochondrial apoptosis pathway and induces apoptosis in HCT-116 cells (Wu et al., 2020).

 2.7.2 Cell cycle block

LA(IC50 = 7 and 8.8 µM, respectively) can prevent the hypoxia-induced proliferation of SW480 and SW620 cells by inhibiting the TrkB/AKT signaling pathway (Arita et al., 2020). LA (5–25 μmol/L) blocked the cell cycle of HCT116 cells at the G1 phase by increasing the level of p21 via inhibition of the JNK1 signaling pathway (Yao et al., 2014).

 2.8 Bladder cancer

Bladder cancer is the 10th most common form of cancer worldwide (Bray et al., 2018). Research has shown that licochalcones can induce apoptosis of bladder cancer cells, inhibit their proliferation, and activate the immune system (Keshavarz-Fathi and Rezaei, 2021).

2.8.1 Induction of apoptosis

By increasing intracellular Ca2+ and ROS levels, decreasing mitochondrial membrane potential, upregulating Apaf-1, caspase-9, caspase-3, and cleaved PARP levels, and elevating the Bax/Bcl-2 ratio, LA (10–80 μM) induced T24 cells apoptosis (Yang et al., 2016; Hong et al., 2019). LB (40–80 μM) induced apoptosis in T24 and EJ cells via decreases in Bcl-2 and survivin expression and enhanced expression of Bax, cleaved PARP, and caspase-3 (Yuan et al., 2014). LC (10–50 μM) induced apoptosis in T24 cells by decreasing Bcl-2, Bcl-w, and Bcl-xL expression levels while increasing Bax and Bim expression levels (Wang et al., 2015).

 2.8.2 Cell cycle block

By downregulating cyclin A, cyclin B1, and Wee1 expression and upregulating the expression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1, LA (10–60 μM) blocked the cell cycle of T24 cells at the G2/M phase (Jiang et al., 2014; Hong et al., 2019). Via decreases in CDK1, CDK2, CDC25A, and CDC25B expression, LB (40–80 μM) led to cell cycle arrest of T24 and EJ cells at the S phase (Yuan et al., 2014).

 2.8.3 Activation of the immune system

In C3H/HeN mice carrying UM-UC-3 cells, LA (40 mg/kg) enhanced the activity of cytotoxic T lymphocytes and increased the number of CD4+ CD25+ Foxp3+ regulatory T cells. This suggests that LA can be used to treat bladder cancer by modulating the immune response (Zhang et al., 2016).

 2.9 Cervical and ovarian cancer

In women, the incidence and mortality rates of cervical and ovarian cancers are lower than those of breast, colorectal, and lung cancers (Bray et al., 2018). Licochalcones can induce autophagy and apoptosis and inhibit the proliferation of cervical and ovarian cancer cells (Keshavarz-Fathi and Rezaei, 2021).

2.9.1 Induction of autophagy

LA (10–50 μM) induced autophagy in SiHa and HeLa cervical cells by increasing the levels of LC3-II, Beclin1, ATG5, ATG7, and ATG12 through inhibition of the PI3K/Akt/mTOR signaling pathway (Tsai et al., 2015).

 2.9.2 Induction of apoptosis

By inhibiting the PI3K/Akt/mTOR signaling pathway, LA (10–50 μM) also induced apoptosis in SiHa, HeLa, CaSki, and C33A cervical cells via upregulation of caspase-3, caspase-9, and cleaved PARP levels and downregulation of Bcl-2 levels (Tsai et al., 2015). In addition, LA (25–50 μM) induces apoptosis in HeLa cells by increasing the expression of TRAIL-R2 (Szliszka et al., 2012). Via induction of ROS production, loss of mitochondrial transmembrane potential, cytochrome c release, increases in Bid and Bax levels, decreases in survivin, Bcl-2, and p53 levels, and activation of the caspase cascade, LA (5–25 μM) induced also the apoptosis in OVCAR-3 and SK-OV-3 ovarian cancer cells (Lee et al., 2012; Kim et al., 2013).

 2.9.2 Cell cycle block

LA (IC50 = 10.7 µM) prevented the hypoxia-induced proliferation of HeLa S3 cells by inhibiting the TrkB/AKT signaling pathway (Arita et al., 2020).

 2.10 Glioma

Glioma is one of the most common primary malignancies of the adult central nervous system (Chen et al., 2021). Licochalcones can induce apoptosis and inhibit the proliferation, migration, and invasion of gliomas (Keshavarz-Fathi and Rezaei, 2021).

2.10.1 Induction of apoptosis

By reducing the mitochondrial membrane potential and the production of ATP, LA (2–12.5 μM) induced mitochondrial fragmentation and caspase-3, -8, and -9 expression in glioma stem cells including GS-Y01, GS-Y03, U87GS, GS-NCC01, and A172GS cells (Kuramoto et al., 2017).

 2.10.2 Cell cycle block

By reducing the cyclin A, cyclin B1, cyclin E1, CDK1, CDK2, and CDK4 expression levels, LA (5–40 μM) induced the cell cycle arrest of glioma U87 cells at the G2/M phase (Lu et al., 2018).

 2.10.3 Inhibition of migration and invasion

By downregulating ADAM9 expression through inhibited activation of the MEK/ERK signaling pathway, LA (10–50 μM) prevented the migration and invasion of human gliomas including M059K, U-251 MG, and GBM8901 cells (Huang et al., 2018).

 2.11 Sarcomas

Sarcomas are a rare, heterogeneous group of malignant tumors of the bone or soft tissue (Walczak and Irwin, 2013). Research has shown that licochalcones can induce autophagy and apoptosis and inhibit the proliferation, migration, and invasion of sarcomas (Keshavarz-Fathi and Rezaei, 2021).

2.11.1 Induction of autophagy

LA (5–20 μmol/L) induced autophagy in A375 and B16 cells by increasing the expression of LC3-II, Beclin1, ATG5, and p62 via activation of the miR-142-3p/Rheb/mTOR signaling pathway (Zhang et al., 2020). By upregulating the LC3A/B-II level, LA (10–40 μM) induced autophagy in osteosarcoma HOS cells (Shen et al., 2019). By suppressing the PI3K/AKT/mTOR pathway, LB (5–20 μM) increased the expression of ARPs (ATG7, Beclin1) and promoted the p62 and LC3B decomposition turnover in MG-63 and U2OS cells, thereby inducing autophagy (Huang and Jin, 2022).

 2.11.2 Induction of apoptosis

By activating the miR-142-3p/Rheb/mTOR signaling pathway, LA (5–20 μmol/L) activated the caspase cascade and induced apoptosis in A375 and B16 cells (Chen et al., 2019; Zhang et al., 2020). In addition, by activating the extrinsic (i.e., upregulation of CHOP, DR4, and DR5 expression) and intrinsic (i.e., inhibition of Sp1 expression) apoptosis pathways, LA (5–20 μM) induced mitochondrial dysfunction, endoplasmic reticulum stress, and ultimately apoptosis in A375 melanoma cells (Kang et al., 2017b). Via increases in caspase-8, caspase-3, and cleaved PARP expression levels and decreases in Bcl-2, XIAP, and survivin expression levels, LA (10–40 μM) induced apoptosis in HOS cells (Shen et al., 2019). By activating the p38 MAPK signaling pathway, increasing the expression of Bax, cleaved PARP, caspase-3, -8, and -9, and decreasing the expression of Bcl-2, LA (20–100 μM) induced apoptosis in osteosarcoma 143B cells (Lin et al., 2019b). Via activation of the death receptor pathway (i.e., increased DR4 and DR5 expression), endoplasmic reticulum stress (i.e., increased CHOP expression), and mitochondrial apoptosis pathway (i.e., increased Bax and cleaved PARP expression and decreased Bcl-xL, Mcl-1, survivin, and Bcl-2 expression), LA (10–40 μM) induced apoptosis in malignant pleural mesothelioma MSTO-211H and H28 cells (Kim et al., 2015). Moreover, LD (20–80 μmol/L) induced the apoptosis in A375 cells by causing a loss in mitochondrial membrane potential, increasing ROS production and Bax, caspase-9, and caspase-3 expression, and downregulating the expression of Bcl-2 (Si et al., 2018).

 2.11.3 Cell cycle block

LA (10–40 μM) induced the cell cycle arrest of HOS cells at the G2/M transition by decreasing the levels of CDC2 and CDC25C via activation of the ATM/Chk2 checkpoint pathway (Shen et al., 2019). Moreover, LA (10–40 μM) blocked the cell cycle of MSTO-211H and H28 cells at the G1 phase by inhibiting cyclin D1 expression (Kim et al., 2015). LA (5–20 μM) also led to cell cycle arrest of HT-1080 cells at the G2 phase by decreasing the levels of CDK1 and CDK2 via inhibition of R132C-mutant isocitrate dehydrogenase 1 (Hu et al., 2020). Furthermore, LA (IC50 = 10.7 µM) inhibited hypoxia-induced proliferation of the neuroblastoma cell lines SK-N-SH, TGW, and GOTO by inhibiting the TrkB/AKT signaling pathway (Arita et al., 2020).

 2.11.4 Inhibition of migration and invasion

By decreasing the expression of MMP-2 and MMP-9, LD (20–80 μmol/L) inhibited the migration and invasion of A375 cells (Si et al., 2018).

 3 Inhibition of the efflux of anticancer drugs

BCRP is an ATP-binding cassette transporter that has an important influence on the metabolism of anticancer drugs. Inhibition of BCRP expression can promote increased intestinal (re)uptake of antineoplastic drugs and decrease their hepatic metabolization, thereby enhancing their bioavailability. In addition to BCRP functions in normal tissues, the overexpression of this transporter in tumors causes multidrug resistance to anticancer drugs such as mitoxantrone, flavonol, and methotrexate (Steinbach et al., 2002; Volk et al., 2002; Tamaki et al., 2010). By reducing the expression of BCRP, LA (10–100 μM) reduced the BCRP-mediated efflux of doxorubicin and temozolomide in BCRP-MDCKII cells. Molecular docking analyses showed that Pi-Pi stacked interactions and potential Pi-Alkyl interactions play important roles (Fan et al., 2019). P-glycoprotein is also an important efflux protein, which mediates the drug resistance of a variety of cancer cells. LA (50–100 μM) reversed the resi stance of KB/MDR1 cells to vinblastine by inhibiting the activity of P-glycoprotein (Nabekura et al., 2015). By inhibiting c-Met overexpression, LA (Chen et al., 2014; Choi et al., 2014; Huang et al., 2014; Tang et al., 2016; Hirsch et al., 2017; Qiu et al., 2017; Chen et al., 2018; Niu et al., 2018; Wang et al., 2018; Lin et al., 2019a; Oh et al., 2019a; Wu et al., 2019; Gao et al., 2021; Heng and Cheah, 2021; Park et al., 2021; Yuan et al., 2021) decreased the activity of HCC827 and PC-9 cells and decreased gefitinib resistance in non-small cell lung cancer cells (Han et al., 2022). For H1975 gefitinib-resistant non-small cell lung cancer cells, LA (10–100 μM) reduced their drug resistance by decreasing Hsp90 activity through binding to the N-terminal ATP binding site of Hsp90 (Seo, 2013).

 4 Review and speculation of the structure-activity relationship

Chalcones are widely recognized as privileged structures, families of molecules featuring scaffolds that upon appropriate decoration can lead to a large spectrum of diverse biological effects. Rossi et al. inserted substituents with different electronic and steric properties into ring B, and altered their positions on the aromatic core, resulting a new range of derivatives. These derivatives induced a remarkable block in G2/M phases, earlier and higher than LA (Rossi et al., 2022). Additionally, approximating to paclitaxel, a series of derivatives of LA (benzimidazole-2-substituted phenyl or pyridine-propylenone) showed significantly better anti-proliferative activity against HCT116, MCF-7 and HepG2 cells than 5-fluorouracil (Wu et al., 2016). Studies have shown that various synthetic LA derivatives are more cytotoxic to cancer cells than naturally occurring licochalcones. Bromo-retrochalcone and trifluoromethyl-retrochalcone can be used as antineoplastic drugs for pleural mesothelioma and oral squamous cell carcinoma with stronger anticancer activity than LA (Yoon et al., 2018). A derivative of LA (LA-linked thiazole-imidazopyridine) has greater antitumor activity than etoposide in MCF-7 and MDA MB-231 breast cancer cells, A549 lung cancer cells, and DU-145 prostate cancer cells (Suma et al., 2020). This indicates that structural modifications of licochalcones to increase their anticancer efficacy are promising.

 5 Conclusion

Studies have shown that licochalcones have a wide range of anticancer activities, such as in gastric, lung, colon, breast, liver, and bladder cancer. Among all licochalcones, LA has the most substantial antitumor effect. Although LA does not have such effects on all types of cancers, it still shows great potential for anticancer treatment. After analyzing and collating the literature, we conclude that the regulation of multiple signaling pathways by licochalcones including the EGFR/ERK, PI3K/Akt/mTOR, p38/JNK, JAK2/STAT3, MEK/ERK, Wnt/β-catenin, and MKK4/JNK signaling pathways is the key to their antineoplastic effects (Figure 2).

The anti-cancer activities and molecular mechanisms of licochalcones.

Among the examined licochalcones, LA not only has antineoplastic effects but also can be used to reduce drug efflux from cancer cells and reduce adverse reactions caused by other antitumor drugs (Herbrechter et al., 2015). Therefore, we believe that the use of LA as an adjunct to anticancer drugs holds great promise. Although licochalcones have demonstrated their value as antitumor drugs, most of these studies are in the cell experiment stage. More clinical studies are needed to confirm the antineoplastic effects of licochalcones. Moreover, except for LA, studies of other licochalcones regarding their anticancer potential are insufficient, making it necessary to further explore the antitumor mechanisms of other licochalcones.

 Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

 Author contributions

ND and MQ contributed equally to this article, participated in the study designed and drafted the manuscript. YL, FL, and JL contributed in manuscript modification. YL oversaw the study. All authors read and approved the final manuscript.

 Funding

This work was supported by National Natural Science Foundation of China (No. 8227151783).

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1074506/full#supplementary-material

References Arita M. Koike J. Yoshikawa N. Kondo M. Hemmi H. (2020). Licochalcone A inhibits bdnf and TrkB gene expression and hypoxic growth of human tumor cell lines. Int. J. Mol. Sci. 21 (2), 506. 10.3390/ijms21020506 Bortolotto L. F. Barbosa F. R. Silva G. Bitencourt T. A. Beleboni R. O. Baek S. J. (2017). Cytotoxicity of trans-chalcone and licochalcone A against breast cancer cells is due to apoptosis induction and cell cycle arrest. Biomed. Pharmacother. 85, 425–433. 10.1016/j.biopha.2016.11.047 Bray F. Ferlay J. Soerjomataram I. Siegel R. Torre L. Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA a cancer J. Clin. 68 (6), 394–424. 10.3322/caac.21492 Chen G. Ma Y. Jiang Z. Feng Y. Han Y. Tang Y. (2018). Lico A causes er stress and apoptosis via up-regulating miR-144-3p in human lung cancer cell line H292. Front. Pharmacol. 9, 837. 10.3389/fphar.2018.00837 Chen R. Lin K. Chen M. Lu W. (2019). Licochalcone A inhibits melanoma cell growth and migration via arresting cell cycle and suppressing Akt phosphorylation. Febs Open Bio 9, 328. Chen X. Liu Z. Meng R. Shi C. Guo N. (2017). Antioxidative and anticancer properties of Licochalcone A from licorice. J. Ethnopharmacol. 198, 331–337. 10.1016/j.jep.2017.01.028 Chen X. J. Guo G. C. Lu Y. L. Wang S. S. Zhang Y. Huang Q. (2021). Mechanisms and functions of long non-coding RNAs in glioma [Review]. Oncol. Rep. 45 (4), 9. 10.3892/or.2021.7960 Chen Z. Fillmore C. M. Hammerman P. S. Kim C. F. Wong K. K. (2014). Non-small-cell lung cancers: A heterogeneous set of diseases. Nat. Rev. Cancer 14 (8), 535–546. 10.1038/nrc3775 Cheng D. Bedford M. T. (2011). Xenoestrogens regulate the activity of arginine methyltransferases. Chembiochem a Eur. J. Chem. Biol. 12 (2), 323–329. 10.1002/cbic.201000522 Cho J. J. Chae J. I. Yoon G. Kim K. H. Cho J. H. Cho S. S. (2014). Licochalcone A, a natural chalconoid isolated from Glycyrrhiza inflata root, induces apoptosis via Sp1 and Sp1 regulatory proteins in oral squamous cell carcinoma. Int. J. Oncol. 45 (2), 667–674. 10.3892/ijo.2014.2461 Choi A. Y. Choi J. H. Hwang K. Y. Jeong Y. J. Choe W. Yoon K. S. (2014). Licochalcone A induces apoptosis through endoplasmic reticulum stress via a phospholipase Cγ1-Ca(2+)-and reactive oxygen species-dependent pathway in HepG2 human hepatocellular carcinoma cells. Apoptosis 19 (4), 682–697. 10.1007/s10495-013-0955-y Fan X. Bai J. Zhao S. Hu M. Sun Y. Wang B. (2019). Evaluation of inhibitory effects of flavonoids on breast cancer resistance protein (BCRP): From library screening to biological evaluation to structure-activity relationship. Toxicol. vitro 61, 104642. 10.1016/j.tiv.2019.104642 Gao F. Li M. Yu X. Liu W. Zhou L. Li W. (2021). Licochalcone A inhibits EGFR signalling and translationally suppresses survivin expression in human cancer cells. J. Cell. Mol. Med. 25 (2), 813–826. 10.1111/jcmm.16135 Gong S. Maegawa S. Yang Y. Gopalakrishnan V. Zheng G. Cheng D. (2020). Licochalcone A is a natural selective inhibitor of arginine methyltransferase 6. Biochem. J. 478, 389–406. 10.1042/bcj20200411 Han S. Li X. Gan Y. Li W. (2022). Licochalcone A promotes the ubiquitination of c-met to abrogate gefitinib resistance. Biomed. Res. Int. 2022, 5687832. 10.1155/2022/5687832 Hao W. J. Yuan X. Yu L. Gao C. X. Sun X. L. Wang D. (2015). Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways. Sci. Rep. 5, 10336. 10.1038/srep10336 Hao Y. Zhang C. Sun Y. Xu H. (2019). Licochalcone A inhibits cell proliferation, migration, and invasion through regulating the PI3K/AKT signaling pathway in oral squamous cell carcinoma. OncoTargets Ther. 12, 4427–4435. 10.2147/ott.s201728 Heng W. S. Cheah S. C. (2021). Identification of phytochemical-based β-catenin nuclear localization inhibitor in NSCLC: Differential targeting population from member of isothiocyanates. Molecules 26 (2), 224. 10.3390/molecules25010224 Herbrechter R. Ziemba P. M. Hoffmann K. M. Hatt H. Werner M. Gisselmann G. (2015). Identification of Glycyrrhiza as the rikkunshito constituent with the highest antagonistic potential on heterologously expressed 5-HT3A receptors due to the action of flavonoids. Front. Pharmacol. 6, 130. 10.3389/fphar.2015.00130 Hirsch F. R. Scagliotti G. V. Mulshine J. L. Kwon R. Curran W. J. Wu Y. L. (2017). Lung cancer: Current therapies and new targeted treatments. Lancet 389 (10066), 299–311. 10.1016/s0140-6736(16)30958-8 Hong S. H. Cha H. J. Hwang-Bo H. Kim M. Y. Kim S. Y. Ji S. Y. (2019). Anti-proliferative and pro-apoptotic effects of licochalcone A through ROS-mediated cell cycle arrest and apoptosis in human bladder cancer cells. Int. J. Mol. Sci. 20 (15), 3820. 10.3390/ijms20153820 Hosseinzadeh H. Nassiri-Asl M. (2015). Pharmacological effects of Glycyrrhiza spp. and its bioactive constituents: Update and review. Phytotherapy Res. PTR 29 (12), 1868–1886. 10.1002/ptr.5487 Hu C. Zuo Y. Liu J. Xu H. Liao W. Dang Y. (2020). Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor. Bioorg. Med. Chem. Lett. 30 (2), 126825. 10.1016/j.bmcl.2019.126825 Huang C. F. Yang S. F. Chiou H. L. Hsu W. H. Hsu J. C. Liu C. J. (2018). Licochalcone A inhibits the invasive potential of human glioma cells by targeting the MEK/ERK and ADAM9 signaling pathways. Food & Funct. 9 (12), 6196–6204. 10.1039/c8fo01643g Huang H. C. Tsai L. L. Tsai J. P. Hsieh S. C. Yang S. F. Hsueh J. T. (2014). Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression. Tumour Biol. 35 (12), 12139–12149. 10.1007/s13277-014-2519-3 Huang W. C. Su H. H. Fang L. W. Wu S. J. Liou C. J. (2019). Licochalcone A inhibits cellular motility by suppressing E-cadherin and MAPK signaling in breast cancer. Cells 8 (3), 218. 10.3390/cells8030218 Huang Z. Jin G. (2022). Licochalcone B induced apoptosis and autophagy in osteosarcoma tumor cells via the inactivation of PI3K/AKT/mTOR pathway. Biol. Pharm. Bull. 45 (6), 730–737. 10.1248/bpb.b21-00991 Jiang J. Yuan X. Zhao H. Yan X. Sun X. Zheng Q. (2014). Licochalcone A inhibiting proliferation of bladder cancer T24 cells by inducing reactive oxygen species production. Bio-medical Mater. Eng. 24 (1), 1019–1025. 10.3233/bme-130899 Kang T. H. Seo J. H. Oh H. Yoon G. Chae J. I. Shim J. H. (2017). Licochalcone A suppresses specificity protein 1 as a novel target in human breast cancer cells. J. Cell. Biochem. 118 (12), 4652–4663. 10.1002/jcb.26131 Kang T. H. Yoon G. Kang I. A. Oh H. N. Chae J. I. Shim J. H. (2017). Natural compound licochalcone B induced extrinsic and intrinsic apoptosis in human skin melanoma (A375) and squamous cell carcinoma (A431) cells. Phytotherapy Res. 31 (12), 1858–1867. 10.1002/ptr.5928 Keshavarz-Fathi M. Rezaei N. (2021). Cancer immunoprevention: Current status and future directions. Archivum Immunol. Ther. Exp. 69 (1), 3. 10.1007/s00005-021-00604-x Kim J-S. Park M-R. Lee S-Y. Kim D. K. Moon S-M. Kim C. S. (2014). Licochalcone A induces apoptosis in KB human oral cancer cells via a caspase-dependent FasL signaling pathway. Oncol. Rep. 31 (2), 755–762. 10.3892/or.2013.2929 Kim K. H. Yoon G. Cho J. J. Cho J. H. Cho Y. S. Chae J. I. (2015). Licochalcone A induces apoptosis in malignant pleural mesothelioma through downregulation of Sp1 and subsequent activation of mitochondria-related apoptotic pathway. Int. J. Oncol. 46 (3), 1385–1392. 10.3892/ijo.2015.2839 Kim Y. J. Jung E. B. Myung S. C. Kim W. Lee C. S. (2013). Licochalcone A enhances geldanamycin-induced apoptosis through reactive oxygen species-mediated caspase activation. Pharmacology 92, 49–59. 10.1159/000351846 Kuramoto K. Suzuki S. Sakaki H. Takeda H. Sanomachi T. Seino S. (2017). Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction. FEBS 7 (6), 835–844. 10.1002/2211-5463.12226 Kwak A. W. Cho S. S. Yoon G. Oh H. N. Lee M. H. Chae J. I. (2020). Licochalcone H synthesized by modifying structure of licochalcone C extracted from Glycyrrhiza inflata induces apoptosis of esophageal squamous cell carcinoma cells. Cell Biochem. biophysics 78 (1), 65–76. 10.1007/s12013-019-00892-3 Kwak A. W. Choi J. S. Liu K. Lee M. H. Jeon Y. J. Cho S. S. (2020). Licochalcone C induces cell cycle G1 arrest and apoptosis in human esophageal squamous carcinoma cells by activation of the ROS/MAPK signaling pathway. J. Chemother. 32. 132–143. 10.1080/1120009X.2020.1721175 Kwon S. J. Park S. Y. Kwon G. T. Lee K. W. Kang Y. H. Choi M. S. (2013). Licochalcone E present in licorice suppresses lung metastasis in the 4T1 mammary orthotopic cancer model. Cancer Prev. Res. 6 (6), 603–613. 10.1158/1940-6207.capr-13-0012 Lee C. S. Kwak S. W. Kim Y. J. Lee S. A. Park E. S. Myung S. C. (2012). Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways. Eur. J. Pharmacol. 683, 54–62. 10.1016/j.ejphar.2012.03.024 Lin R. C. Yang S. F. Chiou H. L. Hsieh S. C. Wen S. H. Lu K. H. (2019). Licochalcone A-induced apoptosis through the activation of p38MAPK pathway mediated mitochondrial pathways of apoptosis in human osteosarcoma cells in vitro and in vivo . Cells 8 (11), 1441. 10.3390/cells8111441 Lin X. Tian L. Wang L. Li W. Xu Q. Xiao X. (2017). Antitumor effects and the underlying mechanism of licochalcone A combined with 5-fluorouracil in gastric cancer cells. Oncol. Lett. 13 (3), 1695–1701. 10.3892/ol.2017.5614 Lin Y. J. Liang W. M. Chen C. J. Tsang H. Chiou J. S. Liu X. (2019). Network analysis and mechanisms of action of Chinese herb-related natural compounds in lung cancer cells. Phytomedicine 58, 152893. 10.1016/j.phymed.2019.152893 Lu W. J. Wu G. J. Chen R. J. Chang C. C. Lien L. M. Chiu C. C. (2018). Licochalcone A attenuates glioma cell growth in vitro and in vivo through cell cycle arrest. Food & Funct. 9 (8), 4500–4507. 10.1039/c8fo00728d Nabekura T. Hiroi T. Kawasaki T. Uwai Y. (2015). Effects of natural nuclear factor-kappa B inhibitors on anticancer drug efflux transporter human P-glycoprotein. Biomed. Pharmacother. 70, 140–145. 10.1016/j.biopha.2015.01.007 Nho S. H. Yoon G. Seo J. H. Oh H. N. Cho S. S. Kim H. (2019). Licochalcone H induces the apoptosis of human oral squamous cell carcinoma cells via regulation of matrin 3. Oncol. Rep. 41 (1), 333–340. 10.3892/or.2018.6784 Niu Q. Zhao W. Wang J. Li C. Yan T. Lv W. (2018). LicA induces autophagy through ULK1/Atg13 and ROS pathway in human hepatocellular carcinoma cells. Int. J. Mol. Med. 41 (5), 2601–2608. 10.3892/ijmm.2018.3499 O'Keefe S. J. D. (2016). Diet, microorganisms and their metabolites, and colon cancer. Nat. Rev. Gastroenterol. Hepatol. 13 (12), 691–706. 10.1038/nrgastro.2016.165 Oh H. Yoon G. Shin J. C. Park S. M. Cho S. S. Cho J. H. (2016). Licochalcone B induces apoptosis of human oral squamous cell carcinoma through the extrinsic- and intrinsic-signaling pathways. Int. J. Oncol. 48 (4), 1749–1757. 10.3892/ijo.2016.3365 Oh H. N. Lee M. H. Kim E. Kwak A. W. Yoon G. Cho S. S. (2020). Licochalcone D induces ROS-dependent apoptosis in gefitinib-sensitive or resistant lung cancer cells by targeting EGFR and MET. Biomolecules 10 (2), 297. 10.3390/biom10020297 Oh H. N. Lee M. H. Kim E. Yoon G. Chae J. I. Shim J. H. (2019). Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET. Phytomedicine Int. J. phytotherapy Phytopharm. 63, 153014. 10.1016/j.phymed.2019.153014 Oh H. N. Oh K. B. Lee M. H. Seo J. H. Kim E. Yoon G. (2019). JAK2 regulation by licochalcone H inhibits the cell growth and induces apoptosis in oral squamous cell carcinoma. Phytomedicine 52, 60–69. 10.1016/j.phymed.2018.09.180 Oh H. N. Seo J. H. Lee M. H. Kim C. Kim E. Yoon G. (2018). Licochalcone C induced apoptosis in human oral squamous cell carcinoma cells by regulation of the JAK2/STAT3 signaling pathway. J. Cell. Biochem. 119 (12), 10118–10130. 10.1002/jcb.27349 Park M. K. Ji J. Haam K. Han T. H. Lim S. Kang M. J. (2021). Licochalcone A inhibits hypoxia-inducible factor-1α accumulation by suppressing mitochondrial respiration in hypoxic cancer cells. Biomed. Pharmacother. 133, 111082. 10.1016/j.biopha.2020.111082 Park M. R. Kim S. G. Cho I. A. Oh D. Kang K. R. Lee S. Y. (2015). Licochalcone-A induces intrinsic and extrinsic apoptosis via ERK1/2 and p38 phosphorylation-mediated TRAIL expression in head and neck squamous carcinoma FaDu cells. Food Chem. Toxicol. 77, 34–43. 10.1016/j.fct.2014.12.013 Pia G. D. M. Sara F. Mario F. Lorenza S. (20192019). Biological effects of licochalcones. Mini-Reviews Med. Chem. 19 (8), 647–656. 10.2174/1389557518666180601095420 Qiu C. Zhang T. Zhang W. Zhou L. Yu B. Wang W. (2017). Licochalcone A inhibits the proliferation of human lung cancer cell lines A549 and H460 by inducing G2/M cell cycle arrest and er stress. Int. J. Mol. Sci. 18 (8), 1761. 10.3390/ijms18081761 Roberts L. S. Yan P. Bateman L. A. Nomura D. K. (2017). Mapping novel metabolic nodes targeted by anti-cancer drugs that impair triple-negative breast cancer pathogenicity. ACS Chem. Biol. 12 (4), 1133–1140. 10.1021/acschembio.6b01159 Rossi M. Cappadone C. Picone G. Bisi A. Farruggia G. Belluti F. (2022). Natural-like chalcones with antitumor activity on human MG63 osteosarcoma cells. Molecules 27 (12), 3751. 10.3390/molecules27123751 Seo J. H. Choi H. W. Oh H. N. Lee M. H. Kim E. Yoon G. (2019). Licochalcone D directly targets JAK2 to induced apoptosis in human oral squamous cell carcinoma. J. Cell. physiology 234 (2), 1780–1793. 10.1002/jcp.27050 Seo Y. H. (2013). Discovery of licochalcone A as a natural product inhibitor of Hsp90 and its effect on gefitinib resistance in non-small cell lung cancer (nsclc). Bull. Korean Chem. Soc. 34 (6), 1917–1920. 10.5012/bkcs.2013.34.6.1917 Shen H. Zeng G. Tang G. Cai X. Bi L. Huang C. (2014). Antimetastatic effects of licochalcone A on oral cancer via regulating metastasis-associated proteases. Tumour Biol. 35 (8), 7467–7474. 10.1007/s13277-014-1985-y Shen T. S. Hsu Y. K. Huang Y. F. Chen H. Y. Hsieh C. P. Chen C. L. (2019). Licochalcone A suppresses the proliferation of osteosarcoma cells through autophagy and ATM-chk2 activation. Molecules 24 (13), 2435. 10.3390/molecules24132435 Si L. Yan X. Hao W. Ma X. Ren H. Ren B. (2018). Licochalcone D induces apoptosis and inhibits migration and invasion in human melanoma A375 cells. Oncol. Rep. 39 (5), 2160–2170. 10.3892/or.2018.6329 Song M. Yoon G. Choi J. S. Kim E. Liu X. Oh H. N. (2020). Janus kinase 2 inhibition by Licochalcone B suppresses esophageal squamous cell carcinoma growth. Phytotherapy Res. 34 (8), 2032–2043. 10.1002/ptr.6661 Steinbach D. Sell W. Voigt A. Hermann J. Zintl F. Sauerbrey A. (2002). BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16 (8), 1443–1447. 10.1038/sj.leu.2402541 Suma V. R. Sreenivasulu R. Rao M. Subramanyam M. Ahsan M. J. Alluri R. (2020). Design, synthesis, and biological evaluation of chalcone-linked thiazole-imidazopyridine derivatives as anticancer agents. Med. Chem. Res. 29 (9), 1643–1654. 10.1007/s00044-020-02590-9 Szliszka E. Jaworska D. Ksek M. Czuba Z. Król W. (2012). Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells. Int. J. Mol. Sci. 13 (11), 15343–15359. 10.3390/ijms131115343 Tamaki H. Satoh H. Hori S. Ohtani H. Sawada Y. (2010). Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug metabolism Pharmacokinet. 25 (2), 170–179. 10.2133/dmpk.25.170 Tang Z. H. Chen X. Wang Z. Y. Chai K. Wang Y. F. Xu X. H. (2016). Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells. Sci. Rep. 6, 26241. 10.1038/srep26241 Tsai J. P. Hsiao P. C. Yang S. F. Hsieh S. C. Bau D. T. Ling C. L. (2014). Licochalcone A suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4/JNK via NF-κB mediated urokinase plasminogen activator expression. PloS one 9 (1), e86537. 10.1371/journal.pone.0086537 Tsai J. P. Lee C. H. Ying T. H. Lin C. L. Lin C. L. Hsueh J. T. (2015). Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells. Oncotarget 6 (30), 28851–28866. 10.18632/oncotarget.4767 Vitorio J. G. Duarte-Andrade F. F. Pereira T. D. F. Fonseca F. P. Amorim L. S. D. Martins-Chaves R. R. (2020). Metabolic landscape of oral squamous cell carcinoma. Metabolomics 16 (10), 105. 10.1007/s11306-020-01727-6 Volk E. L. Farley K. M. Wu Y. Li F. Robey R. W. Schneider E. (2002). Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 62 (17), 5035–5040. Walczak B. E. Irwin R. B. (2013). Sarcoma chemotherapy. J. Am. Acad. Orthop. Surg. 21 (8), 480–491. 10.5435/jaaos-21-08-480 Wang J. Liao A. M. Thakur K. Zhang J. G. Huang J. H. Wei Z. J. (2019). Licochalcone B extracted from Glycyrrhiza uralensis fisch induces apoptotic effects in human hepatoma cell HepG2. J. Agric. food Chem. 67 (12), 3341–3353. 10.1021/acs.jafc.9b00324 Wang J. Wang C. Y. (2021). Integrated miRNA and mRNA omics reveal the anti-cancerous mechanism of licochalcone B on human hepatoma cell HepG2. Food Chem. Toxicol. 150, 112096. 10.1016/j.fct.2021.112096 Wang J. Wei B. Thakur K. Wang C. Y. Li K. X. Wei Z. J. (2021). Transcriptome analysis reveals the anti-cancerous mechanism of licochalcone A on human hepatoma cell HepG2. Front. Nutr. 8, 807574. 10.3389/fnut.2021.807574 Wang J. Zhang Y. S. Thakur K. Hussain S. S. Zhang J. G. Xiao G. R. (2018). Licochalcone A from licorice root, an inhibitor of human hepatoma cell growth via induction of cell apoptosis and cell cycle arrest. Food Chem. Toxicol. 120, 407–417. 10.1016/j.fct.2018.07.044 Wang P. Yuan X. Wang Y. Zhao H. Sun X. Zheng Q. (2015). Licochalcone C induces apoptosis via B-cell lymphoma 2 family proteins in T24 cells. Mol. Med. Rep. 12 (5), 7623–7628. 10.3892/mmr.2015.4346 Wu J. Zhang X. X. Wang Y. H. Sun Q. M. Chen M. Liu S. L. (2018). Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway. Oncol. Rep. 39 (3), 1181–1190. 10.3892/or.2017.6155 Wu L. T. Jiang Z. Shen J. J. Yi H. Zhan Y. C. Sha M. Q. (2016). Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents. Eur. J. Med. Chem. 114, 328–336. 10.1016/j.ejmech.2016.03.029 Wu M. H. Chiu Y. F. Wu W. J. Wu P. L. Lin C. Y. Lin C. L. (2018). Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression. Environ. Toxicol. 33 (12), 1237–1244. 10.1002/tox.22630 Wu P. Yu T. Wu J. Chen J. (2020). Licochalcone a induces ROS-mediated apoptosis through TrxR1 inactivation in colorectal cancer cells. BioMed Res. Int. 2020, 5875074. 10.1155/2020/5875074 Wu R. Li X-Y. Wang W-H. Cai F-F. Chen X-L. Yang M-D. (2019). Network pharmacology-based study on the mechanism of bushen-jianpi decoction in liver cancer treatment. Evidence-Based Complementary Altern. Med. 2019, 1–13. 10.1155/2019/3242989 Xiao X. Y. Hao M. Yang X. Y. Ba Q. Li M. Ni S. J. (2011). Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis. Cancer Lett. 302 (1), 69–75. 10.1016/j.canlet.2010.12.016 Xue L. Zhang W. J. Fan Q. X. Wang L. X. (2018). Licochalcone A inhibits PI3K/Akt/mTOR signaling pathway activation and promotes autophagy in breast cancer cells. Oncol. Lett. 15 (2), 1869–1873. 10.3892/ol.2017.7451 Yang P. Tuo L. Wu Q. Cao X. (2014). Licochalcone-A sensitizes human esophageal carcinoma cells to TRAIL-mediated apoptosis by proteasomal degradation of XIAP. Hepato-gastroenterology 61 (133), 1229–1234. Yang X. Jiang J. Yang X. Han J. Zheng Q. (2016). Licochalcone A induces T24 bladder cancer cell apoptosis by increasing intracellular calcium levels. Mol. Med. Rep. 14 (1), 911–919. 10.3892/mmr.2016.5334 Yao K. Chen H. Lee M. H. Li H. Ma W. Peng C. (2014). Licochalcone A, a natural inhibitor of c-Jun N-terminal kinase 1. Cancer Prev. Res. 7 (1), 139–149. 10.1158/1940-6207.capr-13-0117 Yoon G. Cheon S. H. Shim J. H. Cho S. S. (2018). Design and evaluation of licochalcone a derivatives as anticancer agents. Nat. Product. Commun. 13, 1934578X1801300–689. 10.1177/1934578x1801300609 Yu L. Ma J. Han J. Wang B. Chen X. Gao C. (2016). Licochalcone B arrests cell cycle progression and induces apoptosis in human breast cancer MCF-7 cells. Recent Pat. anti-cancer drug Discov. 11 (4), 444–452. 10.2174/1574892811666160906091405 Yu S. J. Cho I. A. Kang K. R. Jung Y. R. Cho S. S. Yoon G. (2017). Licochalcone-E induces caspase-dependent death of human pharyngeal squamous carcinoma cells through the extrinsic and intrinsic apoptotic signaling pathways. Oncol. Lett. 13 (5), 3662–3668. 10.3892/ol.2017.5865 Yuan L. W. Jiang X. M. Xu Y. L. Huang M. Y. Chen Y. C. Yu W. B. (20212021). Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells. Phytomedicine 80, 153394. 10.1016/j.phymed.2020.153394 Yuan X. Li T. Xiao E. Zhao H. Li Y. Fu S. (2014). Licochalcone B inhibits growth of bladder cancer cells by arresting cell cycle progression and inducing apoptosis. Food Chem. Toxicol. 65, 242–251. 10.1016/j.fct.2013.12.030 Zeng G. Shen H. Yang Y. Cai X. Xun W. (2014). Licochalcone A as a potent antitumor agent suppresses growth of human oral cancer SCC-25 cells in vitro via caspase-3 dependent pathways. Tumour Biol. 35 (7), 6549–6555. 10.1007/s13277-014-1877-1 Zhang J. J. Wu H. D. Wang R. Y. (2021). Metabolic syndrome and esophageal cancer risk: A systematic review and meta-analysis. Diabetology Metabolic Syndrome 13 (1), 8. 10.1186/s13098-021-00627-6 Zhang Y. Gao M. Chen L. Zhou L. Bian S. Lv Y. (2020). Licochalcone A restrains microphthalmia-associated transcription factor expression and growth by activating autophagy in melanoma cells via miR-142-3p/Rheb/mTOR pathway. Phytotherapy Res. 34 (2), 349–358. 10.1002/ptr.6525 Zhang Y. Y. Feng P. P. Wang H. F. Zhang H. Liang T. Hao X. S. (2022). Licochalcone B induces DNA damage, cell cycle arrest, apoptosis, and enhances TRAIL sensitivity in hepatocellular carcinoma cells. Chemico-biological Interact. 365, 110076. 10.1016/j.cbi.2022.110076 Zhang Y. Y. Huang C. T. Liu S. M. Wang B. Guo J. Bai J. Q. (2016). Licochalcone A exerts antitumor activity in bladder cancer cell lines and mice models. Trop. J. Pharm. Res. 15, 1151–1157. 10.4314/tjpr.v15i6.6